rad515utr g135c单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系-relationship between rad 515 utr g135c single nucleotide polymorphism and chemotherapy sensitivity of platinum drugs in advanced non-small cell lung cancer.docxVIP

下载本文档

0
0
约4.42万字
约 10页
2018-06-01 发布于上海
举报
版权申诉

rad515utr g135c单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系-relationship between rad 515 utr g135c single nucleotide polymorphism and chemotherapy sensitivity of platinum drugs in advanced non-small cell lung cancer.docx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

rad515utr g135c单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系-relationship between rad 515 utr g135c single nucleotide polymorphism and chemotherapy sensitivity of platinum drugs in advanced non-small cell lung cancer

PAGE PAGE 4 结果：（1）DNA 修复基因 RAD51 5′-UTR G135C 基因型与 NSCLC 患者的性别、有无吸烟史、临床分期及组织学类型等临床特征无关（P＞0.05）。（2）152 例患者化疗总有效率为 46.7%，携带 RAD51 C-等位基因（G/C+C/C）患者和 G/G 野生纯合子患者化疗有效率分别是 56.7%和 40.2%，前者是后者化疗敏感性的 1.944 倍（OR =1.944，95%CI =1.006-3.758，χ2=3.948，P=0.047）; （3）有吸烟史患者中，携带 RAD51 C-等位基因（G/C+C/C）患者和 G/G 野生纯合子患者化疗有效率分别是 62.1%和 36.9%，前者是后者化疗敏感性的 2.848 倍（OR=2.848，95%CI=1.261-6.430，χ2=6.508，P=0.011），但在不吸烟的患者中差异无统计学意义（P＞0.05）。结论：DNA 修复基因 RAD51 5’-UTR G135C 单核苷酸多态性与晚期非小细胞肺癌铂类化疗敏感性相关。携带 RAD51 G/G 野生纯合子的吸烟的晚期非小细胞肺癌患者铂类化疗敏感性降低。关键词 RAD51; DNA 修复基因；单核苷酸多态；非小细胞肺癌；化疗敏感性 RELATIONSHIP BETWEEN RAD51 5’-UTR G135C POLYMORPHISMS AND THERAPY RESPONSE TO PLATINUM-BASED CHEMOTHERPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS ABSTRACT Objective: Lung cancer is one of the most common maglinant tumors. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all histologic types of lung cancer. Chemotherapy is the main treatment in advanced NSCLC and platinum-based combination chemotherapy regimens are currently recognized as standard first-line one. The RAD51 protein is the key protein for homologous recombination, DNA damage repair and maintains of genetic diversity. The purpose of this study is to investigate the relationship between DNA repair gene RAD51 5’-UTR G135C polymorphisms and chemotherapeutic sensibility of platinum-based regimens in advanced non-small cell lung cancer and to provid theory basis for individual treatment module. Methods: Total of 152 advanced NSCLC patients, who diagnosis pathologically, receiving platinum-based chemotherapy, containing two drugs with cisplatin or carboplatin combined to others, were involved，and clinical response was evaluated after 2 cycles according to response evaluation criteria in solid tumor(RECIST). DNA in peripheral blood leukocytes was obtained, and genotypes were detected by PCR-RFLP method. The PCR amplification was performed by using the following primers: forward (5′- PAGE